



RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

January 24, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on January 24, 2025

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Friday, January 24, 2025, *inter-alia*, considered and approved the following:

1. Unaudited Financial Results of the Company for the quarter ended December 31, 2024.

The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. Intimation about change in Code/Policy

The Board of Directors had approved revision/change in the following Code/Policy:

- Code of Fair Disclosure, Internal Procedures And Conduct for Regulating, Monitoring And Reporting of Trading by Designated Persons and Immediate Relatives of Designated Persons Including Policy on Determination of Legitimate Purpose.
- Policy on Related Party Transactions.

The aforesaid amended code/policy and above information shall be made available on the Company's website at <https://www.rpglifesciences.com/>

The meeting commenced at 03:00 p.m. and concluded at 5.45 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH
RAMESH SHIRAMBEKAR
Date: 2025.01.24 19:01:51
+05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended December 31, 2024 and year to date from April 1, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



SRBC & COLLP

Chartered Accountants

5. We draw attention to Note 5 of the financial results, which describes the potential effects arising on account of fire in a production facility of the Company subsequent to the quarter ended December 31, 2024. Our conclusion is not modified in respect of this matter.

For SRBC & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

Aruna

per Aruna Kumaraswamy

Partner

Membership No.: 219350

UDIN: 252193508MLZZW3857

Place: Mumbai

Date: January 24, 2025



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Particulars	Quarter ended			Nine months ended		(Rs. in Lakhs)
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	Year ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	17,271	17,221	15,370	51,034	45,506	58,205
2 Other Income	331	194	192	762	556	721
3 Total Income (1+2)	17,602	17,415	15,562	51,796	46,062	58,926
4 Expenses						
(a) Cost of Materials Consumed	3,019	2,081	2,485	8,337	9,262	12,065
(b) Purchases of Stock-in-Trade	2,270	2,633	1,649	7,392	4,626	6,118
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	322	703	683	800	421	270
(d) Employee Benefits Expense	2,871	3,309	3,369	9,454	10,007	13,215
(e) Finance Costs	12	17	14	44	31	45
(f) Depreciation and Amortisation Expense	546	531	414	1,606	1,258	1,707
(g) Other Expenses	3,873	3,902	3,394	11,635	10,447	13,722
Total Expenses	12,913	13,176	12,008	39,268	36,052	47,142
5 Profit before exceptional items and tax (3-4)	4,689	4,239	3,554	12,528	10,010	11,784
6 Exceptional items (Refer Note 3)	-	(2,730)	-	(2,730)	-	-
7 Profit before tax	4,689	1,509	3,554	9,798	10,010	11,784
8 Income tax expenses						
a. Current Tax	1,192	1,078	950	3,221	2,709	3,254
b. Deferred Tax	4	11	(42)	(12)	(141)	(236)
Total tax expenses	1,196	1,089	908	3,209	2,568	3,018
9 Profit for the period (7-8)	3,493	420	2,646	6,589	7,442	8,766
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	2	3	2	7	7	(75)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	(1)	(1)	(3)	(3)	19
Other Comprehensive Income Net of Tax	1	2	1	4	4	(56)
11 Total Comprehensive Income for the period (9+10)	3,494	422	2,647	6,593	7,446	8,710
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						36,162
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	21.12	2.54	16.00	39.84	45.00	53.01
(b) Diluted (in Rs.)	21.12	2.54	16.00	39.84	45.00	53.01

SIGNED FOR IDENTIFICATION
BY

S R B C & CO LLP
MUMBAI



Notes:

1. The above unaudited financial results have been reviewed and recommended by the Audit Committee at its meeting held on January 23, 2025 and have been approved by the Board of Directors at its meetings held on January 24, 2025.
2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
3. Exceptional items for the period ended December 31, 2024 represents transfer charges of INR 2,730 lakhs paid by the Company, pursuant to the receipt of the order dated September 12, 2024 from Maharashtra Industrial Development Corporation (MIDC), Navi Mumbai in response to the Company's application under amnesty scheme as per Government Resolution (GR) dated July 26, 2024 (as amended) in respect of levy of transfer charges towards assignment of portion of leasehold rights made in earlier periods under the Urban Land (Ceiling and Regulation) Act, 1976.
4. The Company has executed a binding agreement dated September 13, 2024 with M/s. KRSNA Dynasty, an unrelated party, for assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai for a consideration of INR 14,563 lakhs plus applicable GST (subject to applicable income tax deducted at source). The transaction is subject to satisfactory completion of the Conditions Precedent in the agreement and obtaining necessary approvals which are currently underway and the same is expected to be completed in Q4 FY25.
5. On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Company located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai – 400703, Maharashtra. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in the incidence. The said incident has an impact on part of the Building, Plant & Machinery, inventories and other assets of the said block. The Company is in the process of estimating the extent of damage caused and loss arising on account of such damage. The Company believes that all the assets in the said plant are adequately covered under insurance, necessary intimation to insurance company has already been given and the Company expects to receive first tranche of interim payment soon. The Company is fully engaged in restricting the business loss from such interruption to the lowest possible extent. Since, this is a non-adjusting subsequent event, no adjustment has been made in the financial results for the quarter and period ended December 31, 2024.



For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, January 24, 2025

